JP2025508129A5 - - Google Patents
Info
- Publication number
- JP2025508129A5 JP2025508129A5 JP2024553795A JP2024553795A JP2025508129A5 JP 2025508129 A5 JP2025508129 A5 JP 2025508129A5 JP 2024553795 A JP2024553795 A JP 2024553795A JP 2024553795 A JP2024553795 A JP 2024553795A JP 2025508129 A5 JP2025508129 A5 JP 2025508129A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition according
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317943P | 2022-03-08 | 2022-03-08 | |
| US63/317,943 | 2022-03-08 | ||
| PCT/US2023/063996 WO2023172989A2 (en) | 2022-03-08 | 2023-03-08 | Epo receptor agonists and antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508129A JP2025508129A (ja) | 2025-03-21 |
| JP2025508129A5 true JP2025508129A5 (https=) | 2026-03-18 |
Family
ID=87935923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553795A Pending JP2025508129A (ja) | 2022-03-08 | 2023-03-08 | Ｅｐｏ受容体アゴニストおよびアンタゴニスト |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20250129147A1 (https=) |
| EP (1) | EP4490187A4 (https=) |
| JP (1) | JP2025508129A (https=) |
| KR (1) | KR20250007062A (https=) |
| CN (1) | CN119365486A (https=) |
| AU (1) | AU2023232105A1 (https=) |
| CA (1) | CA3255594A1 (https=) |
| IL (1) | IL315499A (https=) |
| WO (2) | WO2023172989A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202300015063A1 (it) * | 2023-07-18 | 2025-01-18 | Andremacon S R L | Metodo per potenziare l'efficacia dell'immunoterapia e potenziare la risposta immunitaria dell'ospite |
| CN117017974A (zh) * | 2023-09-12 | 2023-11-10 | 南京鼓楼医院 | 水飞蓟宾在制备治疗系统性红斑狼疮的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1169352A4 (en) * | 1999-04-14 | 2005-05-04 | Smithkline Beecham Corp | ANTIBODY AGAINST THE ERYTHROPOIETIN RECEPTOR |
| WO2003037377A1 (fr) * | 2001-11-02 | 2003-05-08 | Takeda Chemical Industries Ltd | Agents prophylactiques/therapeutiques destines aux maladies des organes a evolution chronique, aux maladies arthritiques chroniques, aux cicatrices hypertrophiques ou cheloides |
| JP4299527B2 (ja) * | 2001-11-02 | 2009-07-22 | 佳子 安田 | 増殖性臓器疾患、慢性関節炎症性疾患、肥厚性瘢痕またはケロイド予防・治療剤 |
| US7160697B2 (en) * | 2002-08-21 | 2007-01-09 | Duke University | Use of novel cytokine receptors as biomarkers and therapeutic targets in human cancer |
| WO2008065372A2 (en) * | 2006-11-28 | 2008-06-05 | Nautilus Biotech, S.A. | Modified erythropoietin polypeptides and uses thereof for treatment |
| GB0812277D0 (en) * | 2008-07-04 | 2008-08-13 | Fusion Antibodies Ltd | Antibody and uses thereof |
| US9254311B2 (en) * | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| WO2022025204A1 (ja) * | 2020-07-30 | 2022-02-03 | エポメッド株式会社 | ＥｐｏＲアンタゴニストによる疾患の処置 |
-
2023
- 2023-03-08 AU AU2023232105A patent/AU2023232105A1/en active Pending
- 2023-03-08 JP JP2024553795A patent/JP2025508129A/ja active Pending
- 2023-03-08 CN CN202380039511.1A patent/CN119365486A/zh active Pending
- 2023-03-08 IL IL315499A patent/IL315499A/en unknown
- 2023-03-08 WO PCT/US2023/063996 patent/WO2023172989A2/en not_active Ceased
- 2023-03-08 US US18/844,737 patent/US20250129147A1/en active Pending
- 2023-03-08 CA CA3255594A patent/CA3255594A1/en active Pending
- 2023-03-08 WO PCT/US2023/063997 patent/WO2023172990A2/en not_active Ceased
- 2023-03-08 EP EP23767673.9A patent/EP4490187A4/en active Pending
- 2023-03-08 US US18/844,732 patent/US20250129170A1/en active Granted
- 2023-03-08 KR KR1020247033372A patent/KR20250007062A/ko active Pending
-
2025
- 2025-08-26 US US19/310,073 patent/US20260116986A1/en active Pending
- 2025-09-02 US US19/317,120 patent/US20250388687A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11952425B2 (en) | High affinity B7-H6 antibodies and antibody fragments | |
| CN110511278B (zh) | 抗b7-h6抗体、融合蛋白及其使用方法 | |
| JP7834148B2 (ja) | Ｔ細胞活性化のための抗体 | |
| KR20210030406A (ko) | Cd137 항원-결합 부위를 포함하는 fc 결합 단편 | |
| JP7010487B2 (ja) | 抗コチニン抗体が連結したキメラ抗原受容体およびその使用 | |
| CN107847587A (zh) | Cd30×cd16抗体与pd‑1拮抗剂的联合药物用于治疗 | |
| JP2021524275A (ja) | ＯＸ４０抗原結合部位を含むＦｃ結合断片 | |
| JP2025508066A (ja) | 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体 | |
| JP2025508129A5 (https=) | ||
| JP2022523804A (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| Wang et al. | An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers | |
| JP2026026083A (ja) | がんの治療のための多重特異性抗体 | |
| CN113728009A (zh) | 双特异性CD123 x CD3双抗体在血液系统恶性肿瘤治疗中的给药方案 | |
| WO2022093694A1 (en) | Polypeptides targeting hpv peptide-mhc complexes and methods of use thereof | |
| KR20250160456A (ko) | Tnf 슈퍼패밀리 멤버 면역사이토카인 및 이의 용도 | |
| JP2026506647A (ja) | 多重特異性γδＴＣＲ抗体を含む組み合わせ療法 | |
| WO2024085182A1 (ja) | Ｔ細胞性腫瘍の治療剤 | |
| US20250353931A1 (en) | Multi-specific reagent for targeted delivery of lipid nanoparticles | |
| JP2025515473A (ja) | 改変された細胞傷害性ｔ細胞およびその使用方法 | |
| HK40056381A (en) | Humanized anti-dll3 chimeric antigen receptors and uses thereof |